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global consensus that we also need better estimates of any
long-term donor risks.1,2 In an often-cited Swedish study,
living kidney donors lived longer than the general
population.3 However, donors go through a rigorous
evaluation process to confirm good health, and risks
would be better estimated by comparing a group of donors
to the healthiest segment of the general population.
To our knowledge, no published study has considered
whether cardiovascular events are increased after kidney
donation.
There are a few important reasons to evaluate the risk of
cardiovascular disease. First, donors appear to have
5 mm Hg increase in blood pressure above that attributable
to normal aging;4 in the general population, every
10 mm Hg increase in systolic blood pressure or 5 mm Hg
increase in diastolic blood pressure is associated with a 1.5-
fold increase in mortality from both ischemic heart disease
and stroke. This risk extends well into the ‘normal’ range
of blood pressure. Hypertension is one of the most
important causes of cardiovascular disease worldwide,
and was noted to be higher in one donor study but not
others.4 Second, psychological stress has been associated
with premature cardiovascular disease. A small percentage
of donors experience significant anxiety from the dona-
tion,5 and from having a loved one with kidney failure.
Third, in the general population, a glomerular filtration
rate (GFR) of 60–89 mL/min has been independently
associated with premature cardiovascular disease. This
new baseline level of GFR is realized by more than half of
all kidney donors.6 Some donors go on to develop lower
levels of GFR,6 or as Dr Sehayi describes it ‘chronically
decreased GFR.’1
Dr Sehayi’s data on coronary artery calcification is
indeed reassuring. What we now need is further informa-
tion, which meets modern epidemiologic standards for
accurate risk assessment. This includes future record
linkage studies and more resource intensive, prospective
cohort studies. The ideal controls may be those individuals
identified as healthy potential donors who do not undergo
the operation. Inclusion of racially diverse, older and
genetically related donors will help define whether there
are differential effects of donation among these indivi-
duals. Such efforts will improve donor selection and the
informed consent process. As highlighted by Dr Sehayi,1
such efforts will also guide care that maintains good long-
term health for previous and future living donors.
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To the Editor: Although the use of surrogate end points
instead of hard clinical end points for the drug FDA (Food
and Drug Administration) market authorization is currently
challenged,1 we acknowledge that the promotion of sevela-
mer over calcium phosphate binder is now based on harder
evidence than coronary calcifications, as in a randomized
trial with 37 deaths occurring in incident dialysis patients,
mortality was found borderline lower.2
It should be noted, however, that the patients were likely
vitamin D insufficient,3 but receiving 1-a-OH-vitamin D
derivatives which, when compared with cholecalciferol,
are increasing vascular calcification risk as shown by a
comparison of two German cohorts of young adults with
childhood onset of end-stage renal disease:4 in Heidelberg,
the prevalence of coronary calcification was 92%, whereas
in East Berlin it was 10%, the main therapeutical difference
being a 35-fold lower cumulative dose of potentiated vitamin D
yielding. In addition, a better parathyroid suppression
(150 vs 360 pg ml1 of intact parathyroid hormone) was
observed in Berlin.
Therefore, to actually establish a superiority of sevelamer
over calcium phosphate binder, a larger trial should compare
two strategies: sevelamerþ potentiated vitamin D with
cholecalciferolþCaCO3.
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